

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claim 12 as follows:

1-11. (canceled).

12. (currently amended) A composition comprising a peptide ~~comprising~~ consisting of the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), in which the peptide is conjugated to a carrier protein.

13. (canceled).

14. (previously presented) A method of treating cancer comprising:
administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;
wherein the peptide comprises the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1).

15-17. (canceled).

18. (previously presented) The method of claim 14 wherein the monoclonal antibody is humanized.

19. (previously presented) The method of claim 14 wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

20. (previously presented) The method of claim 14 wherein the cancer is prostate cancer or breast cancer.

21. (previously presented) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising:

administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide;

wherein the peptide comprises the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1).

22-24. (canceled).

25. (previously presented) The method of claim 21 wherein the monoclonal antibody is humanized.

26. (previously presented) The method of claim 21 wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

27. (previously presented) The method of claim 21 wherein the disease or condition is atherosclerosis.

28. (previously presented) The composition of claim 12 further comprising an adjuvant.

29. (previously presented) A composition comprising a peptide comprising up to 45 amino acids, and comprising the sequence EDGIKRIQDD (SEQ ID NO:2).

30. (previously presented) The composition of claim 29 in which the peptide is conjugated to a carrier protein.

31. (previously presented) The method of claim 14 wherein the antibody fragment is a Fab, F(ab')₂, Fv, or scFv fragment.

32. (previously presented) The method of claim 21 wherein the antibody fragment is a Fab, F(ab')₂, Fv, or scFv fragment.